MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from controlled
equity offering sales...
$87,784K
Proceeds from issuance of
common stock upon...
$8,603K
Proceeds from employee
stock purchase plan
$1,002K
Stock-based compensation
$32,238K
Accounts payable,
accrued liabilities,...
$21,289K
Reduction in the carrying
amount of right of use...
$2,408K
Depreciation
$1,770K
Impairment of right of use
asset
$696K
Loss on disposal of
property and equipment
-$145K
Net cash provided by
financing activities
$97,389K
Net cash provided by
(used in) operating...
$45,585K
Canceled cashflow
$12,961K
Net decrease in
cash, cash...
-$43,838K
Canceled cashflow
$142,974K
Sales of marketable
securities
$136,580K
Net loss
-$6,885K
Accounts receivable
$4,268K
Amortization and accretion of
marketable securities
-$1,133K
Prepaid expenses and
other current assets
$545K
Deferred revenue
-$130K
Net cash used in
investing activities
-$186,812K
Canceled cashflow
$136,580K
Purchases of marketable
securities
$322,722K
Purchases of property and
equipment
$670K
Back
Back
Cash Flow
source: myfinsight.com
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)